Article
Lung adenocarcinoma harboring concomitant EGFR mutation and EML4-ALK fusion that benefits from three kinds of tyrosine kinase inhibitors: a case report and literature review.
Clinical lung cancer - 1 Mar 2015
Zhao Ning, Zheng Shu-yi, Yang Jin-ji, Zhang Xu-chao, Xie Zhi, Xie Bin, Su Jian, Chen Zhi-hong, Chen Shi-liang, Zhang Na, Lou Na-na, Dong Song, Wu Yi-long
Abstract excerpt
No abstract is available from the source.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.